Opko Health, Inc. (OPK): Gamma Investments Trust Frost , CEO of Opko Health, Inc. purchased 7,600 shares on Apr 15, 2016. The Insider buying transaction was reported by the company on Apr 18, 2016 to the Securities and Exchange Commission. The shares were purchased at $10.78 per share for a total value of $81,926.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 7, 2016, Gamma Investments Trust Frost (CEO) purchased 20,000 shares at $10.59 per share price.On Mar 18, 2016, Jane Ph D Hsiao (Vice Chairman & CTO) purchased 1,200 shares at $10.65 per share price.Also, On Sep 15, 2015, Adam Logal (CFO) purchased 1,000 shares at $9.95 per share price.On Aug 20, 2015, Steven D Rubin (Executive VP-Administration) purchased 2,000 shares at $12.40 per share price.
Shares of Opko Health (OPK) ended Friday, Apr 15, 2016 session in red amid volatile trading. The shares closed down -0.02 points or -0.18% at $10.8 with 19,75,956 shares getting traded. Post opening the session at $10.8, the shares hit an intraday low of $10.63 and an intraday high of $10.89 and the price vacillated in this range throughout the day. The company has a market cap of $5,895 M and the number of outstanding shares has been calculated to be 54,58,40,060 shares. The 52-week high of Opko Health is $19.2 and the 52-week low is $7.1225.
Company has been under the radar of several Street Analysts.Opko Health is Reiterated by Barrington Research to Outperform while Lowering the Price Target of the company shares to $ 16 from a previous price target of $17 . The Rating was issued on Mar 31, 2016.
Currently the company Insiders own 47.76% of Opko Health shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by 0.03%.Institutional Investors own 20.72% of Opko Health shares.During last six month period, the net percent change held by insiders has seen a change of 0.03%.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.